Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Allopurinol
Accord Healthcare Ireland Ltd.
M04AA; M04AA01
Allopurinol
300 milligram(s)
Tablet
Preparations inhibiting uric acid production; allopurinol
Marketed
2019-07-19
DE/H/5351/001-002/II/010, version 01, Jan 2024 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ALLOPURINOL 100 MG TABLETS ALLOPURINOL 300 MG TABLETS allopurinol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Allopurinol is and what it is used for 2. What you need to know before you take Allopurinol 3. How to take Allopurinol 4. Possible side effects 5. How to store Allopurinol 6. Contents of the pack and other information 1. WHAT ALLOPURINOL IS AND WHAT IT IS USED FOR Allopurinol contains the active substance allopurinol. This medicine belongs to a group of medicines called enzyme inhibitors, which control the speed at which certain chemical changes occur in your body. Allopurinol is used to treat conditions where too much uric acid is produced by your body such as: gout; certain types of kidney disease and kidney stones; cancer and some enzyme disorders which lead to the build-up of too much uric acid. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ALLOPURINOL DO NOT TAKE ALLOPURINOL: • if you are allergic to allopurinol or any of the other ingredients of this medicine (listed in section 6). If you are not sure, check with your doctor first before taking the medicine. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Allopurinol if • you are suffering, or have you suffered, from liver or kidney disease • you are taking medicines (diuretics and/or a medicine called ACE inhibitors) for heart disease or high blood pressure • you are experiencing an acute attack of gout • y Διαβάστε το πλήρες έγγραφο
Health Products Regulatory Authority 19 February 2024 CRN00F4JX Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Allopurinol 300 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 300 mg Allopurinol. Excipients with known effect: Each 300 mg tablet contains 99 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White to off white, round, biconvex with beveled edge uncoated tablet with inscription "AX" on one side and plain on the other side having approximate diameter of 11.2 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: -Idiopathic gout; -Uric acid lithiasis; -Acute uric acid nephropathy; -Neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; -Certain enzyme disorders which lead to overproduction of urate, for example: -Hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; -Glucose-6-phosphatase including glycogen storage disease; -Phosphoribosylpyrophosphate synthetase; -Phosphoribosylpyrophosphate amidotransferase; -Adenine phosphoribosyltransferase; Allopurinol is indicated for the management of 2, 8-dihydroxyadenine (2, 8-DHA) renal stones related to deficient activity of adenine phosphoribosyltranferase. Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed. Children and adolescents -Secondary hyperuricaemia of differing origin -Uric acid nephropathy during tr Διαβάστε το πλήρες έγγραφο